Big, Easy-to-Take News for Lipocine

Big, Easy-to-Take News for Lipocine

By: Dylan Sikes - News=

Thursday, March 14, 2019

More breakthroughs in the medical research field: Salt Lake City-based specialty pharmaceutical company Lipocine Inc. (NASDAQ:LPCN) announced Thursday it’s been picked to present LPCN 1144 clinical results as part of ENDO 2019, being held next weekend in New Orleans.

A news release out Thursday said the presentation will highlight the therapeutic potential of LPCN 1144 in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.  

Lipocine is in the business of developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. Its flagship product, TLANDO, a novel oral prodrug of testosterone containing what's called testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men.

Shares in Lipocine rocketed 13 cents, or 6.5%, to $2.16, on share volume of 229,000. 

Copyright © 2019 All rights reserved. Republication or redistribution of's content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Pot Stock Ready To Resume Multi-Month Uptrend
Martello Technologies Leaps on Fiscal 2019 Figures
Progressive Care Makes Progress on Revenues, Stock Price.
GelTech Wins Federal Nod, Shares Take Flight

Back to Top